Cite

HARVARD Citation

    Redell, M. et al. (2018). A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program. Open forum infectious diseases. p. . [Online]. 
  
Back to record